IRS Releases Final Revised Form 6765 for Tax Year 2024
IRS Releases Final Form 6765 for 2024: Key Updates for R&D Tax Credit Filings On February 10th this year, the IRS released the final version of Form 6765, on which taxpayers claim the Credit for Increasing Research Activities for tax years 2024 and onward. The calculation of the credit under either the Traditional Method in […]
R&D Tax Credits and Section 174: What’s Next for Your Business?
Join our experts, Devin Medrek and Savannah Durham, for a webinar on key tax strategies for your business. Learn how the R&D Tax Credit can boost your finances before the March 15th and April 15th deadlines. We’ll cover the Section 174 impact, ways to combine R&D and Section 174 strategies for maximum tax savings, and […]
Harnessing Innovation: How Advanced Manufacturers Can Leverage R&D Tax Credits
Introduction to Advanced Manufacturing Innovation is the lifeblood of the advanced manufacturing sector. Companies within this industry continually push the boundaries of technology, improve production processes, and develop new materials to stay competitive. However, many businesses overlook a significant financial incentive designed to support their efforts: the Research & Development (R&D) tax credit. This federal […]
The R&D Tax Credit and Contract Manufacturing Organizations
The R&D Tax Credit The Credit for Increasing Research Activities, otherwise known as the R&D Tax Credit, is governed by Internal Revenue Code (IRC) §41, and has long been used by innovative companies to decrease their tax burden and increase research activities within the business. To qualify for the R&D Tax Credit, the activities performed […]
Complete a Section 174 Compliance Study with Leyton
Under Section 174, the required information for R&D claims has changed. Discover what is needed and how Leyton can help!
Webinar Replay, Reclaim Funds From Clinical Trials: The Orphan Drug Tax Credit
Orphan Drug Tax Credit – Background and Changes Leyton is the source for tax education! Watch our webinar to dive into the ODTC Tax Credit qualifications and changes to ensure you’re up to date. Agenda Q&AOverview of The Orphan Drug Tax Credit Qualification for The Orphan Drug Tax Credit Detail about rare diseases and why […]
IRS Eases Requirements for Claiming R&D Credit: Updated Guidance on Documentation for Section 41
Historical Context – October 2021 On October 15, 2021, the IRS issued IR-2021-203, introducingnew procedures for taxpayers seeking a refund claim for the Research Credit under Section 41. Effective January 10, 2022, taxpayers were required to provide specific information to validate their claims. The essential documentation included: *Update – June 2024 In a significant update […]
Harness the Power of the Orphan Drug Tax Credit with Leyton
At Leyton, we’re not just about maximizing tax incentives; we’re about fueling innovation and growth. While the R&D Tax Credit (RDTC) might be a familiar tool in your arsenal, we’re excited to shed light on another potent tax-saving instrument: the Orphan Drug Tax Credit (ODTC). The ODTC is a federal tax incentive aimed at spurring […]
Form 6765: Credit for Increasing Research Activities
What is the Research and Development Tax Credit? The R&D Tax Credit, officially titled the Credit for Increasing Research Activities, is a permanent dollar for dollar offset to a company’s tax liability for performing activities that satisfy the IRS’ criteria. The credit was first enacted in 1981 and has since been made permanent in 2015, […]
The R&D Shrink Back Rule
Overview: The Research and Development (“R&D”) Tax Credit is a federal incentive for companies conducting qualified research activities and is codified by Section 41 of the Internal Revenue Code (“IRC”). IRC §41(d) sets forth the four-part test that must be satisfied in order for a company’s research activities to qualify for the credit. However, if […]